Schrodinger Inc. (NASDAQ: SDGR) reported Q3 EPS of ($0.45), $0.26 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $54.32 million versus the consensus estimate of $49.64 million.

2025 Financial Outlook
Today Schrödinger updated its 2025 full-year guidance for software revenue growth, drug discovery revenue, and software gross margin. The company’s financial expectations for the fiscal year ending December 31, 2025 are as follows:

Software revenue growth is now expected to range from 8% to 13% compared to the prior expectation of 10% to 15%.
Drug discovery revenue is now expected to range from $49 million to $52 million compared to the prior expectation of $45 million to $50 million.
Software gross margin is now expected to range from 73% to 75% compared to the prior expectation of 74% to 75%.
Operating expenses in 2025 are expected to be lower than 2024.
Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024.

For earnings history and earnings-related data on Schrodinger Inc. (SDGR) click here.